Antibody Neutralizing Human Respiratory Syncytial Virus
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 8 of these applications claim priority to application 62/367,359, filed Jul 27, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,963,500 | Antibody Neutralizing Human Respiratory Syncytial Virus In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | ||
| US 10,072,072 | Antibody Neutralizing Human Respiratory Syncytial Virus In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | ||
| US 10,323,079 | Antibody Neutralizing Human Respiratory Syncytial Virus In force · Medium confidence | Merck Sharp & Dohme LLC | In force | Medium confidence | ||
| US 10,358,480 | Antibody Neutralizing Human Respiratory Syncytial Virus In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | ||
| US 11,008,380 | Antibody Neutralizing Human Respiratory Syncytial Virus In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | ||
| US 11,981,726 | Antibody Neutralizing Human Respiratory Syncytial Virus In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | ||
| US 12,371,478 | Antibody Neutralizing Human Respiratory Syncytial Virus In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | ||
| US 11,566,065 | Antibody Neutralizing Human Respiratory Syncytial Virus In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | ||
| Application 19/250,874 | Antibody Neutralizing Human Respiratory Syncytial Virus Pending Not granted | Merck Sharp & Dohme LLC | Pending | Not granted |
9 of 9 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
8 of these are in force and held by Merck Sharp and Dohme LLC.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.